Nanobiotix/NBTX

$5.41

-1.63%
-
1D1W1MYTD1YMAX

About Nanobiotix

Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Ticker

NBTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Laurent Levy

Employees

101

Headquarters

Paris, France

Nanobiotix Metrics

BasicAdvanced
$261.97M
Market cap
-
P/E ratio
-$1.80
EPS
0.29
Beta
-
Dividend rate
$261.97M
0.29478
$11.00
$1.75
37.45K
0.675
-6.62%
-97.14%
-411.11%
-36.5%

What the Analysts think about Nanobiotix

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 3 analysts.
120.33% upside
High $12.80
Low $10.91
$5.41
Current price
$11.92
Average price target

Nanobiotix Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q2 23
QoQ growth
Revenue
€0
-
Net income
€-28M
-8.5%
Profit margin
0%
-

Nanobiotix Earnings Performance

Earnings per share (EPS)

Company profitability
-
QuarterlyAnnual
Q4 23
Actual
-
Expected
-€0.82
Surprise
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Nanobiotix stock?

Nanobiotix (NBTX) has a market cap of $261.97M as of April 19, 2024.

What is the P/E ratio for Nanobiotix stock?

The price to earnings (P/E) ratio for Nanobiotix (NBTX) stock is 0 as of April 19, 2024.

Does Nanobiotix stock pay dividends?

No, Nanobiotix (NBTX) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Nanobiotix dividend payment date?

Nanobiotix (NBTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Nanobiotix?

Nanobiotix (NBTX) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Nanobiotix stock price target?

The target price for Nanobiotix (NBTX) stock is $11.92, which is 120.33% above the current price of $5.41. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Nanobiotix stock

Buy or sell Nanobiotix stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing